Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers

Pharmaceutical Research

Volumn 29, Issue 6, 2012, Pages 1518-1529

  Trocóniz, Iñaki F ^a   Boland, Katja ^b   Staab, Alexander ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

flibanserin; NONMEM; PKPD modeling; sedation

Indexed keywords

FLIBANSERIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; GOOD CLINICAL PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PHARMACODYNAMICS; POPULATION MODEL; PRIORITY JOURNAL; SEDATION; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; BENZIMIDAZOLES; COMPUTER SIMULATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; SLEEP STAGES; TABLETS;

EID: 84862675611     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0648-6     Document Type: Article

References (27)

1. American Psychiatric Association. DSM-IV: Diagnostic and statistical manual f mental disorders, 4th edition. Text revision. Washington: American Psychiatric Press; 2000.
2. JL Shifren BU Monz PA Russo A Segreti CB Johannes 2008 Sexual problems and distress in United States women: prevalence and correlates Obstet Gynecol. 112 5 970 978 18978095 10.1097/AOG.0b013e3181898cdb
3. RW Invernizzi G Sacchetti S Parini S Acconcia R Samanin 2003 Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors Br J Pharmacol. 139 7 1281 1288 12890707 10.1038/sj.bjp.0705341 1:CAS:528:DC%2BD3sXmvVCisro%3D
4. S Kennedy 2010 Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder J Sex Med. 7 10 3449 3459 20646181 10.1111/j.1743-6109.2010.01938.x 1:CAS:528:DC%2BC3cXhsFemu7bK
5. B Ferger M Shimasaki A Ceci C Ittrich KA Allers B Sommer 2010 Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats Naunyn Schmiedebergs Arch Pharmacol. 381 6 573 579 20422156 10.1007/s00210-010-0515-8 1:CAS:528:DC%2BC3cXlvFegtbc%3D
6. A Newman-Tancredi P Heusler JC Martel AM Ormière N Leduc D Cussac 2008 Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells Int J Neuropsychopharmacol. 11 3 293 307 17897483 10.1017/S1461145707008061 1:CAS:528:DC%2BD1cXktFCrtbc%3D
7. Boehringer Ingelheim. Briefing document, Flibanserin Tablet, NDA 22-526 Reproductive Health Drugs Advisory Committee Meeting, June 18, 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ UCM215438.pdf
8. NONMEM Users Guides. Beal SL, Sheiner LB, Boeckmann AJ, editors. Icon Development Solutions, Ellicott City, Maryland, USA; 1989-2006.
9. MO Karlsson LB Sheiner 1993 The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Biopharm. 21 6 735 750 8138894 10.1007/BF01113502 1:STN:280:DyaK2c7os12huw%3D%3D
10. AC Hooker CE Staatz MO Karlsson 2007 Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method Pharm Res 24 12 2187 2197 17612795 10.1007/s11095-007-9361-x 1:CAS:528:DC%2BD2sXht1KrtrjN
11. TM Ludden SL Beal LB Sheiner 1994 Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection J Pharmacokinet Biopharm. 22 5 431 445 7791040 10.1007/BF02353864 1:STN:280:DyaK2MzhtFWgsg%3D%3D
12. L Lindbom J Ribbing EN Jonsson 2004 Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming Comput Methods Programs Biomed. 75 2 85 94 15212851 10.1016/j.cmpb.2003.11.003
13. E Comets K Brendel F Mentré 2008 Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R Comput Methods Programs Biomed. 90 2 154 166 18215437 10.1016/j.cmpb.2007.12.002
14. NH Holford RJ Ambros K Stoeckel 1992 Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil J Pharmacokinet Biopharm. 20 5 421 442 1287195 10.1007/BF01061464 1:CAS:528:DyaK3sXhtFKiu7k%3D
15. RM Savic DM Jonker T Kerbusch MO Karlsson 2007 Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies J Pharmacokinet Pharmacodyn. 34 5 711 726 17653836 10.1007/s10928-007- 9066-0 1:CAS:528:DC%2BD2sXhtVOitr%2FI
16. DeBoor. A practical guide to splines. New York: Springer Verlag; 1998.
17. LB Sheiner DR Stanski S Vozeh RD Miller J Ham 1979 Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin Pharmacol Ther. 25 3 358 371 761446 1:CAS:528:DyaE1MXhsl2qsro%3D
18. RW Ostelo RA Deyo P Stratford G Waddell P Croft M Von Korff, et al. 2008 Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change Spine (Phila Pa 1976) 33 1 90 94 10.1097/BRS.0b013e31815e3a10
19. MO Karlsson RM Savic 2007 Diagnosing model diagnostics Clin Pharmacol Ther. 82 1 17 20 17571070 10.1038/sj.clpt.6100241 1:STN:280: DC%2BD2szlvVakug%3D%3D
20. Van Dongen HPA, Dinges DF. Circadian rhythm in sleepiness, alertness and performance. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 4th ed. Philadelphia: Saunders; 2005. p. 435-43.
21. DR Drover MS Angst M Valle B Ramaswamy S Naidu DR Stanski, et al. 2002 Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers Anesthesiology. 97 4 827 836 12357147 10.1097/00000542-200210000-00013 1:CAS:528:DC%2BD38XnsVejurw%3D
22. M Josa JP Urizar J Rapado C Dios-Viéitez G Castañeda- Hernández F Flores-Murrieta, et al. 2001 Pharmacokinetic/pharmacodynamic modeling of antipyretic and anti-inflammatory effects of naproxen in the rat J Pharmacol Exp Ther. 297 1 198 205 11259545 1:CAS:528:DC%2BD3MXisVSrsb4%3D
23. A Staab C Tillmann ST Forgue A Mackie SR Allerheiligen J Rapado, et al. 2004 Population dose-response model for tadalafil in the treatment of male erectile dysfunction Pharm Res. 21 8 1463 1470 15359583 10.1023/B:PHAM. 0000036922.03519.40 1:CAS:528:DC%2BD2cXmtlGnur4%3D
24. S Kshirsagar R Gear J Levine D Verotta 2008 A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain J Pharmacokinet Pharmacodyn. 35 1 69 83 17943420 10.1007/s10928-007-9076-y 1:CAS:528:DC%2BD1cXkvFahs7w%3D
25. I Ortega JJ Perez-Ruixo K Stuyckens V Piotrovsky A Vermeulen 2010 Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials J Clin Pharmacol. 50 3 293 310 20056804 10.1177/0091270009346057 1:CAS:528:DC%2BC3cXjvFyrt74%3D
26. AM Luks MS Zwass RC Brown M Lau G Chari DM Fisher 1998 Opioid-induced analgesia in neonatal dogs: pharmacodynamic differences between morphine and fentanyl J Pharmacol Exp Ther. 284 1 136 141 9435171 1:CAS:528: DyaK1cXltlCltg%3D%3D
27. MJ Garrido M Valle MA Campanero R Calvo IF Trocóniz 2000 Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats J Pharmacol Exp Ther. 295 1 352 359 10992001 1:CAS:528:DC%2BD3cXnt1yns74%3D